Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy

Lancet

Volumn 347, Issue 8997, 1996, Pages 297-299

  Jensen, B V ^a   Nielsen, S L ^a   Skovsgaard, T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPIRUBICIN; FUROSEMIDE; RAMIPRIL;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COUGHING; FEMALE; HEART DILATATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0030071726     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90469-9     Document Type: Article

References (12)

1. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-17.
2. Mortensen SA, Aabo K, Jonsson T, Baandrup U. Clinical and noninvasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection. Int J Clin Pharmacol Res 1986; 6: 137-50.
3. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 1827-34.
4. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990; 8: 1806-10.
5. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
6. Haq MM, Legha SS, Choksi J, et al. Doxorubicin-induced congestive heart failure in adults. Cancer 1985; 56: 1361-65.
7. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy - risk factors. Cancer 1977; 39: 1397-402.
8. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
9. Brynjolf I, Kelbaek H, Munck O, Godtfredsen J, Larsen S, Eriksen J. Right and left ventricular ejection fraction and left ventricular volume changes at rest and during exercise in normal subjects. Eur Heart J 1984; 5: 756-61.
10. Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubucin and doxorubucin: assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722-27.
11. Caulfield JB, Bittner V. Cardiac matrix alterations induced by adriamycin. Am J Pathol 1988; 133: 298-305.
12. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.